{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T08:10:00Z","timestamp":1783152600446,"version":"3.54.6"},"reference-count":10,"publisher":"American Society of Hematology","issue":"8","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,2,25]]},"DOI":"10.1182\/blood.2020009269","type":"journal-article","created":{"date-parts":[[2021,2,25]],"date-time":"2021-02-25T17:11:36Z","timestamp":1614273096000},"page":"1011-1012","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":2,"title":["CNS relapse in DLBCL: a calculable risk?"],"prefix":"10.1182","volume":"137","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0009-8138","authenticated-orcid":false,"given":"Gerald","family":"Illerhaus","sequence":"first","affiliation":[{"name":"Klinikum Stuttgart"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2021022516333368800_B1","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2020007236","article-title":"Genomic subtypes may predict the risk of central nervous system recurrence in diffuse large B-cell lymphoma","author":"Ollila","year":"2021","journal-title":"Blood"},{"issue":"15","key":"2021022516333368800_B2","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa1801445","article-title":"Genetics and pathogenesis of diffuse large B-cell lymphoma","volume":"378","author":"Schmitz","year":"2018","journal-title":"N Engl J Med"},{"issue":"5","key":"2021022516333368800_B3","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41591-018-0016-8","article-title":"Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes [published corrections in Nat Med. 2018;24:1292 and Nat Med. 2018;24:1290-1291]","volume":"24","author":"Chapuy","year":"2018","journal-title":"Nat Med"},{"issue":"7","key":"2021022516333368800_B4","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1182\/blood-2015-10-673236","article-title":"Targetable genetic features of primary testicular and primary central nervous system lymphomas","volume":"127","author":"Chapuy","year":"2016","journal-title":"Blood"},{"issue":"10","key":"2021022516333368800_B5","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1016\/j.jmoldx.2020.07.002","article-title":"Analysis of driver mutational hot spots in blood-derived cell-free DNA of patients with primary central nervous system lymphoma obtained before intracerebral biopsy","volume":"22","author":"Montesinos-Rongen","year":"2020","journal-title":"J Mol Diagn"},{"issue":"11","key":"2021022516333368800_B6","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/S1470-2045(11)70235-2","article-title":"CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group","volume":"12","author":"Pfreundschuh","year":"2011","journal-title":"Lancet Oncol"},{"issue":"26","key":"2021022516333368800_B7","doi-asserted-by":"crossref","first-page":"3150","DOI":"10.1200\/JCO.2015.65.6520","article-title":"CNS International Prognostic Index: a risk model for CNS relapse in patients with diffuse large B-cell lymphoma treated with R-CHOP","volume":"34","author":"Schmitz","year":"2016","journal-title":"J Clin Oncol"},{"issue":"9","key":"2021022516333368800_B8","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1182\/blood-2018-07-862862","article-title":"Integration of cell of origin into the clinical CNS International Prognostic Index improves CNS relapse prediction in DLBCL","volume":"133","author":"Klanova","year":"2019","journal-title":"Blood"},{"issue":"5","key":"2021022516333368800_B9","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1111\/bjh.13194","article-title":"Risk-tailored CNS prophylaxis in a mono-institutional series of 200 patients with diffuse large B-cell lymphoma treated in the rituximab era","volume":"168","author":"Ferreri","year":"2015","journal-title":"Br J Haematol"},{"issue":"4","key":"2021022516333368800_B10","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.ccell.2020.03.015","article-title":"A probabilistic classification tool for genetic subtypes of diffuse large B cell lymphoma with therapeutic implications","volume":"37","author":"Wright","year":"2020","journal-title":"Cancer Cell"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/137\/8\/1011\/1800884\/bloodbld2020009269c.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/137\/8\/1011\/1800884\/bloodbld2020009269c.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,26]],"date-time":"2021-04-26T12:39:13Z","timestamp":1619440753000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/137\/8\/1011\/475256\/CNS-relapse-in-DLBCL-a-calculable-risk"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,25]]},"references-count":10,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,2,25]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2020009269","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,25]]}}}